Ingenia Therapeutics expects $5 million MK-8748 milestone payment from Merck unit Eyebiotech
MRK•Ingenia Therapeutics expects a $5 million milestone payment from Merck unit Eyebiotech after the start of a global Phase 3 trial of MK-8748 for diabetic macular edema. The invoice was issued on Sept. 25, 2026.
1. Milestone payment
Ingenia Therapeutics expects to receive a $5 million payment tied to MK-8748, which it licensed to Merck unit Eyebiotech in 2022. The payment was triggered by the start of a global Phase 3 trial in diabetic macular edema; an invoice issued Sept. 25, 2026, marked the milestone confirmation date under the license agreement.
